Vizora日本語

EisaiEisai Co., Ltd.4523東証プライム医薬品FY ending Mar 2024, consolidated, IFRS

Eisai FY ending Mar 2019 results

Eisai brought in ¥642.8B in revenue.

Out of every ¥100 of sales, about ¥13 is left as operating profit.

Revenue changed +7.1% from the prior year, operating profit +11.6%.

Revenue and profit pattern

Revenue and profit upProfit grew faster

Revenue +7.1% · profit +11.6%, calculated from disclosed figures.

Operating leverage: 1.62× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2018 → FY ending Mar 2019

Revenue
+7.1%¥600.1B → ¥642.8B
Operating income
+11.6%¥77.2B → ¥86.2B
Net income attributable to owners
+22.3%¥51.8B → ¥63.4B
Operating cash flow
-30.7%¥149.6B → ¥103.7B

Where the money goes

FY ending Mar 2018 → FY ending Mar 2019

※ Cost of revenue is not disclosed; expenses are combined

Where ¥100 of sales goes

For every ¥100 Eisai sells, how much goes where, and how much is kept.

FY ending Mar 2019
Operating costs
¥87
Operating profit
¥13
Net profit kept
¥10

Annual margin trends

Operating margin13.4%
FY ending Mar 2017: 11.0%11.0%FY ending Mar 2018: 12.9%12.9%FY ending Mar 2019: 13.4%13.4%FY17FY18FY19
Net margin9.9%
FY ending Mar 2017: 7.3%7.3%FY ending Mar 2018: 8.6%8.6%FY ending Mar 2019: 9.9%9.9%FY17FY18FY19

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (3)

  • EDINET (FSA Japan)

    有価証券報告書－第111期(2022/04/01－2023/03/31)

    ID S100R09Z2023-06-21Open

  • EDINET (FSA Japan)

    有価証券報告書－第110期(令和3年4月1日－令和4年3月31日)

    ID S100O9U72022-06-17Open

  • EDINET (FSA Japan)

    有価証券報告書－第109期(令和2年4月1日－令和3年3月31日)

    ID S100LKNM2021-06-18Open

Extracted from XBRL: 19 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image